US 12,357,615 B2
Compositions for the treatment of brain tumors
Joel Eisner, Chapel Hill, NC (US); Daniel Wahl, Ann Arbor, MI (US); and Corey Speers, Ann Arbor, MI (US)
Assigned to Kembi Therapeutics Pty Ltd, Carlton (AU); The Regents of the University of Michigan, Ann Arbor, MI (US); and The United States Government as represented by The Department of Veterans Affairs, Washington, DC (US)
Appl. No. 17/284,200
Filed by Kembi Therapeutics Pty Ltd, Carlton (AU); The Regents of the University of Michigan, Ann Arbor, MI (US); and The United States Government as represented by The Department of Veterans Affairs, Washington, DC (US)
PCT Filed Oct. 11, 2019, PCT No. PCT/US2019/055818
§ 371(c)(1), (2) Date Apr. 9, 2021,
PCT Pub. No. WO2020/077197, PCT Pub. Date Apr. 16, 2020.
Claims priority of provisional application 62/744,342, filed on Oct. 11, 2018.
Prior Publication US 2022/0370415 A1, Nov. 24, 2022
Int. Cl. A61K 31/4192 (2006.01); A61K 31/4375 (2006.01); A61K 31/573 (2006.01); A61K 35/00 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07D 249/04 (2006.01)
CPC A61K 31/4192 (2013.01) [A61K 31/4375 (2013.01); A61K 31/573 (2013.01); A61P 35/00 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating a subject suffering from a brain tumor, wherein the brain tumor is a glioma, meningioma, or medulloblastoma, the method comprising the administration of radiation therapy and an effective amount of a pharmaceutical composition comprising: (1) seviteronel, or a pharmaceutically acceptable salt thereof, (2) dexamethasone, or a pharmaceutically acceptable salt thereof; and (3) a pharmaceutically acceptable carrier.